BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251211T190000
DTEND;TZID=Africa/Nairobi:20251211T203000
DTSTAMP:20260423T205651
CREATED:20251208T194713Z
LAST-MODIFIED:20251208T201236Z
UID:40719-1765479600-1765485000@kesho-kenya.org
SUMMARY:Bladder and Urothelial Cancer Treatment
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Moderator:  \nDr. Thomas OdenyMedical Oncologist\, Assistant Professor of Medicine\,Washington University in St. Louis \nSpeakers: \nDr. Primus OchiengLecturer\, Programme Director – MMed Radiation Oncology& Founder\, UNITED Oncology Clinical Trial Centre\, UoNRadiotherapy in Bladder Cancer: Current Evidence and Clinical Applications \nDr. DK KimaniConsultant Surgeon & Urologist\, Kenyatta National Hospital\, NairobiBladder & Urothelial Cancer in Kenya: Bridging Treatment Innovations and Local Realities \nDr. Andrea ApolloSenior Investigator\, Genitourinary Malignancies Branch\, NCI\, USAManagement of bladder cancer: Clinical trials and research updates \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_r-GmQ2UNQ5a2J_g3WFZKPg”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/bladder-and-urothelial-cancer-treatment/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/12/Bladder-and-Urothelial-1-e1765223155779.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251204T190000
DTEND;TZID=Africa/Nairobi:20251204T203000
DTSTAMP:20260423T205651
CREATED:20251208T200234Z
LAST-MODIFIED:20251223T171606Z
UID:40728-1764874800-1764880200@kesho-kenya.org
SUMMARY:Cancer-Related Thrombosis
DESCRIPTION:Cancer-Associated Thrombosis: From Primary to Secondary Prophylaxis\nPresentation by Dr Laura Kirui\nDr Laura Kirui delivered a focused clinical update on cancer-associated thrombosis (CAT)\, addressing its epidemiology\, pathophysiology and evidence-based prevention and treatment strategies across the cancer care continuum. \nThe presentation highlighted the significantly increased risk of venous thromboembolism (VTE) among cancer patients and its associated morbidity and mortality. Mechanistic insights into cancer-driven hypercoagulability including inflammation\, dysregulated fibrinolysis\, and tumor host cellular interactions were reviewed to contextualize clinical risk. \nEmphasis was placed on risk stratification\, particularly the use of validated tools such as the Khorana score\, to guide decisions on primary thromboprophylaxis. Data supporting the use of low molecular weight heparin and selected direct oral anticoagulants in high-risk populations were discussed\, alongside bleeding considerations. The session also addressed therapeutic anticoagulation\, duration of treatment\, secondary prophylaxis and management in special scenarios including thrombocytopenia\, catheter-related thrombosis and incidental VTE. \nKey takeaway: Individualized risk assessment and ongoing reassessment are central to optimizing prevention and management of cancer-associated thrombosis.
URL:https://kesho-kenya.org/event/cancer-related-thrombosis/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/12/WhatsApp-Image-2025-12-08-at-10.54.41-PM-e1765224285156.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251127T190000
DTEND;TZID=Africa/Nairobi:20251127T203000
DTSTAMP:20260423T205651
CREATED:20251125T134829Z
LAST-MODIFIED:20251125T135434Z
UID:40713-1764270000-1764275400@kesho-kenya.org
SUMMARY:Management of Pancreatic Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nCPD ACCREDITED \nManagement of Pancreatic Cancer \nDate:27th November 2025 \nTime:7 PM – 8:30 PM EAT \n\nModerator \nDr. Karan GandhiConsultant Hepatobiliary\, General and Laparoscopic Surgeon at 3rd Park Hospital\, Nairobi \n\nSPEAKER \nDr. Sakulen A HarguraConsultant Hepatobiliary\, General & Laparoscopic Surgeon\, Kenyatta University Teaching\, Research and Referral Hospital\, NairobiTopic: Surgical Dilemmas in Pancreatic Cancer\, “Who\, When & How” \n\nSPEAKER \nDr. Andrew OdhiamboMedical Oncologist – The Nairobi HospitalThematic Head & Program Director – Medical Oncology\, UONTopic: Balancing Quality Vs Quantity of Life – Oncologist Role in Stage 4 Pancreatic Cancer \nSPEAKER \nJoyce AwuorConsultant Dietitian Nutritionist\, Founder and CEO of DietSelect254Topic: The Ideal Diet for A Failing Pancreas \nKESHOKenya Society of Haematology & Oncology \n[/vc_column_text][vc_btn title=”CLICK TO REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_LBsnGVB-T6u9uhilBFGe0w”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-pancreatic-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-25-at-10.01.18-AM-e1764078640953.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251120T190000
DTEND;TZID=Africa/Nairobi:20251122T203000
DTSTAMP:20260423T205651
CREATED:20251118T071137Z
LAST-MODIFIED:20251223T172117Z
UID:40558-1763665200-1763843400@kesho-kenya.org
SUMMARY:Management of Non-Small Cell Lung Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nBRIDGING DISCIPLINES:ADVANCES IN THE COMPREHENSIVEManagement of Non-Small Cell Lung Cancer \nDate: 20th November 2025Time: 7 PM – 8:30 PM EAT \n(CPD ACCREDITED) \n\nModerator\nDr. Muhindi WanjuguPhysician and Chest Specialist\, The Nairobi Hospital\, Doctors Plaza\, Nairobi \n\nSpeakers\nDr. Nuruddin JoomaHaemato-Oncologist\, Florida Cancer Specialists & Research Institute\, USASystemic Therapy Advances in Non-Small-Cell Lung Cancer \nDr. Morris MuhingaConsultant Cardiothoracic Surgeon\, The Nairobi HospitalShift in Surgical Paradigm \nSummary: \nLung Cancer: Contemporary Clinical Management and Emerging Evidence \nPresentations by Dr Nuruddin Jooma and Dr Morris Muhinga \nThe sessions delivered by Dr Nuruddin Jooma and Dr Morris Muhinga provided a clinically focused overview of lung cancer management\, with emphasis on Non-Small Cell Lung Cancer (NSCLC) across early\, locally advanced and metastatic diseases. The presentations underscored the central role of accurate histological classification\, TNM staging and multidisciplinary evaluation in determining treatment intent and sequencing. \nKey clinical principles discussed included optimal diagnostic pathways incorporating imaging\, histopathology and immunohistochemistry\, alongside the increasing importance of molecular profiling. Biomarker testing particularly for actionable driver mutations such as EGFR was highlighted as essential to guide therapy selection\, avoid inappropriate use of immunotherapy and improve survival outcomes. \nCurrent standards of care were reviewed across disease stages\, including surgical management in early-stage disease\, the expanding role of neoadjuvant and adjuvant systemic therapies\, consolidation strategies following chemoradiation in locally advanced disease and the use of targeted therapies in molecularly defined metastatic NSCLC. Landmark clinical trials informing contemporary practice were referenced to illustrate evolving treatment paradigms. \nBoth presentations reinforced the need for timely diagnosis\, biomarker-driven treatment decisions and coordinated multidisciplinary care\, while acknowledging ongoing challenges related to access\, treatment sequencing and long-term disease control. \nKey takeaway: Optimal lung cancer outcomes depend on precise staging\, comprehensive molecular testing and evidence-based\, multidisciplinary treatment across the disease continuum.
URL:https://kesho-kenya.org/event/management-of-non-small-cell-lung-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-17-at-10.34.44-PM-e1763449878610.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251113T190000
DTEND;TZID=Africa/Nairobi:20251113T203000
DTSTAMP:20260423T205651
CREATED:20251110T143627Z
LAST-MODIFIED:20251223T151933Z
UID:40551-1763060400-1763065800@kesho-kenya.org
SUMMARY:Advances in Small-Cell Lung Cancer Treatment
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nDate: 13th November 2025Time: 7 PM – 8:30 PM EAT \n\nSpeakerDr. Riaz KasmaniMedical Oncologist\, Mombasa Cancer CentreSmall-Cell Lung Cancer: Advances\, Evidence and Clinical Challenges \n\nModeratorDr. Jumaa BwikaClinical Assistant Professor & Section Head\, Pulmonology\, Aga Khan Hospital \n\nOrganized by:KESHOKenya Society of Haematology & Oncology \nSupported by:BEACON Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited) \nSummary: \nDr Kasmani presented an overview of Small Cell Lung Cancer (SCLC)\, focusing on disease biology\, treatment response\, relapse patterns and emerging research directions. \nSCLC accounts for a minority of lung cancer diagnoses yet contributes disproportionately to cancer-related mortality due to its aggressive behavior\, early dissemination and rapid development of treatment resistance. While the disease is initially highly chemo sensitive\, with high response rates to first-line therapy\, relapse is common and subsequent responses are often short-lived. \nThe presentation highlighted current staging approaches\, standard first-line treatment strategies for limited and extensive-stage disease and the evolving role of chemo-immunotherapy. Emphasis was placed on response assessment\, patterns of relapse and the clinical distinction between sensitive and refractory disease\, which continues to guide second-line treatment decisions. \nKey takeaway: Despite high initial response rates\, SCLC remains a challenging disease with frequent relapses\, underscoring the need for timely diagnosis\, evidence-based treatment and continued investment in research and clinical trials to improve patient outcomes.
URL:https://kesho-kenya.org/event/lung-cancer-treatment/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/11/WhatsApp-Image-2025-11-10-at-1.44.04-PM-e1762785377526.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251030T190000
DTEND;TZID=Africa/Nairobi:20251030T203000
DTSTAMP:20260423T205651
CREATED:20251029T090350Z
LAST-MODIFIED:20251223T153247Z
UID:40485-1761850800-1761856200@kesho-kenya.org
SUMMARY:Multidisciplinary Management of Hepatocellular Carcinoma
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nMultidisciplinary Management of Hepatocellular Carcinoma(CPD Accredited) \nDate: 30th October 2025Time: 7:00 PM – 8:30 PM EAT \nModerator:Dr. Wycliffe KaishaConsultant Gastrointestinal & Hepato-Bilio-Pancreatic Surgeon\, Hercules Healthcare \nSpeakers: \n\nDr. Gladwell KiarieMedical Oncologist\, The Nairobi HospitalTopic: The Medical Oncologists’ Role in HCC: Emerging Trends\nDr. Eric MurungaConsultant Physician\, Gastroenterologist; Chairman\, Gastroenterology Society of KenyaTopic: Management of Hepatitis B in Low-Resource Settings\nDr. Samuel NgukuConsultant\, Radiology and Nuclear Medicine\, Aga Khan University Hospital\, NairobiTopic: Imaging of Hepatocellular Carcinoma\n\nOrganized by:Kenya Society of Haematology & Oncology (KESHO) \nPartner:Beacon Medicare Limited(Global Marketing Partner of BEACON Pharmaceuticals Limited) \nSummary: \nThe Chronic Liver Disease–Hepatocellular Carcinoma Continuum: Practical Clinical Updates \nPresentations by Dr Gladwell Kiarie and Dr Eric Murunga \nTwo complementary presentations examined the clinical continuum linking chronic liver disease to hepatocellular carcinoma (HCC)\, with a focus on pragmatic\, evidence-based approaches applicable to resource-limited settings. \nDr Gladwell Kiarie reviewed the medical management of hepatocellular carcinoma\, emphasizing the importance of stage-guided\, individualized care. Using established staging frameworks\, she highlighted how tumor burden\, liver function and patient performance status collectively inform treatment selection. The discussion underscored the evolving role of systemic therapies\, including immunotherapy and targeted agents\, alongside locoregional modalities such as trans arterial therapies and radiotherapy. The need for multidisciplinary decision-making\, early referral and appropriate patient selection was reinforced as critical to improving outcomes in HCC. \nDr Eric Murunga addressed the management of chronic Hepatitis B within real-world\, resource-constrained contexts. He outlined practical diagnostic pathways\, treatment eligibility criteria and monitoring strategies aligned with contemporary guidelines. Emphasis was placed on simplified fibrosis assessment tools\, long-term antiviral therapy and structured follow-up. Preventive strategies including screening\, vaccination of contacts and hepatocellular carcinoma surveillance were highlighted as essential interventions to reduce progression to cirrhosis and liver cancer. \nTogether\, the presentations reinforced the concept that HCC prevention and outcomes are intrinsically linked to effective upstream management of chronic liver disease\, particularly viral hepatitis. \nKey takeaway: Strengthening early identification and treatment of chronic Hepatitis B\, alongside structured surveillance and stage-appropriate management of hepatocellular carcinoma\, is central to reducing advanced liver cancer and improving survival in resource-limited settings.
URL:https://kesho-kenya.org/event/multidisciplinary-management-of-hepatocellular-carcinoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-28-at-2.53.20-PM-e1761728953517.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251023T190000
DTEND;TZID=Africa/Nairobi:20251023T203000
DTSTAMP:20260423T205651
CREATED:20251022T122025Z
LAST-MODIFIED:20251022T124234Z
UID:40475-1761246000-1761251400@kesho-kenya.org
SUMMARY:Advancing Breast Cancer Survivorship Care in Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nTheme: Evidence\, Outcomes & Psychosocial PerspectivesDate: 23rd October 2025Time: 7:00 PM – 8:30 PM EATCPD Accredited \nSpeakers & Topics: \n1. Zahra Haji \n\nPsycho-oncologist & Associate Scientist\nPsychosocial Oncology Lead\, DART Lead Kenya; Aga Khan University Hospital Nairobi\nTopic: The Emotional Journey of Survivorship: Addressing Psychological Well-being after Breast Cancer\n\n2. Prisca Githuka \n\nVice-Chairperson & Advocacy Chair\, Kenyan Network of Cancer Organizations (KENCO); Chairlady\, Cancer Survivors Association of Kenya; Founder and Team Leader – Pink Hearts Cancer Support Foundation\nTopic: Lived Experience of Breast Cancer Survivors in Kenya: Gaps and Implications for Care\n\n3. Dr. Joyfrida Chepchumba \n\nPharmacist & Program Officer – Treatment\, Palliative Care and Survivorship Pillar\, National Cancer Control Program\nTopic: Policy Frameworks for Breast Cancer Survivorship Care in Kenya\n\n4. Lyagamula (Gammy) Kisia \n\nResearch Officer\, African Population and Health Research Center (APHRC)\, Kenya\nTopic: Breast Cancer Survivorship in Kenya: Key Findings from a Pilot Study\n\nModerator:  Dr. Miriam Mutebi\n\nConsultant Breast Surgical Oncologist & Health Systems Researcher\, Aga Khan University in Nairobi\, Kenya\n\nOrganizers & Partners:\n\nKESHO (Kenya Society of Hematology & Oncology)\nNCCP (National Cancer Control Programme)\nKILELE Health Association\nKENCO (Kenyan Network of Cancer Organizations)\nAPHRC (African Population and Health Research Center)\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_b8KShWmmTw6SEdqZgvXY6Q”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/advancing-breast-cancer-survivorship-care-in-kenya/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-22-at-12.24.06-AM-e1761135614607.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251021T190000
DTEND;TZID=Africa/Nairobi:20251021T203000
DTSTAMP:20260423T205651
CREATED:20251014T073256Z
LAST-MODIFIED:20251016T162549Z
UID:40451-1761073200-1761078600@kesho-kenya.org
SUMMARY:Digital Health: A Breast Cancer Journey
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\nDate: 21st October 2025\nTime: 7 PM – 8:30 PM (EAT)\nCPD Accredited\n\nModerator: \n\nDr. Sitna Ali Mwanzi – Consultant Medical Oncologist\, Kenyatta National Hospital\n\nSpeakers: \n\nDr. Matiko Riro – Health Economist & CEO\, Savannah Global Health Institute (SGHI)Topic: The Role of Data in Health Financing for Oncology – Use case Herceptin SC Access program\nDr. Ngure Nyaga – Healthcare Innovator & Technologist\, Savannah InformaticsTopic: Leveraging Digital Solutions\, Data & AI to Optimise Patient Outcomes in Oncology\nDr. Gladwell Kiarie – Medical Oncologist\, The Nairobi HospitalTopic: Optimising Outcomes in Cancer Care – The Breast Cancer Patient Journey\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_btn title=”ONLINE REGISTRATION” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_NwAtGBXoSgumue-28Yk7XA”][/vc_column][/vc_row][vc_row][vc_column width=”1/2″][vc_btn title=”PHYSICAL REGISTRATION FORM” color=”danger” css=”” link=”url:https%3A%2F%2Fforms.gle%2FqoV5reYJByoGNTi46″][/vc_column][vc_column width=”1/2″][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/a-breast-cancer-journey/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-16-at-4.37.46-PM-e1760631816635.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251015T080000
DTEND;TZID=Africa/Nairobi:20251015T170000
DTSTAMP:20260423T205651
CREATED:20251015T142554Z
LAST-MODIFIED:20251015T142716Z
UID:40467-1760515200-1760547600@kesho-kenya.org
SUMMARY:Advancing Care in HER2 Positive Breast Cancer
DESCRIPTION:Date: 9th October 2025\nTime: 7 PM – 8:30 PM (EAT)CPD Accredited\n\nSpeakers\n\n\nDr. Manel Haj MansourConsultant Medical Oncologist & Section Head of Medical Oncology\, Aga Khan University Hospital\, NairobiTopic: Early and Locally Advanced HER2 Positive Breast Cancer — Evolving Strategies in Diagnosis\, Treatment\, and Long-Term Outcomes. \n\n\nDr. Angela McligeyoPhysician and Medical OncologistTopic: Metastatic HER2 Positive Breast Cancer — Optimizing Outcomes Through Novel Therapies and Multidisciplinary Care. \n\n\nModerator\n\nDr. Catherine NyongesaDirector of Medical Services\, Kenyatta National Hospital & Co-founder\, Texas Cancer Centre\, Nairobi.
URL:https://kesho-kenya.org/event/advancing-care-in-her2-positive-breast-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/10/WhatsApp-Image-2025-10-09-at-10.07.52-AM-e1760538332676.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20251002T190000
DTEND;TZID=Africa/Nairobi:20251002T203000
DTSTAMP:20260423T205651
CREATED:20250930T124046Z
LAST-MODIFIED:20251223T171811Z
UID:40444-1759431600-1759437000@kesho-kenya.org
SUMMARY:Triple Negative Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nTriple Negative Breast Cancer: Early and Late Stage Management(CPD Accredited) \nDate & Time: \n\n2nd October 2025\n7 PM – 8:30 PM (EAT)\n\nSpeaker: Dr. Joseph AbuodhaConsultant Medical Oncologist\, Department of Haematology and Oncology\, Aga Khan University Hospital\, NairobiTopic: Triple-Negative Breast Cancer: Advancing Care Across Early and Late Stages \nModerator: Dr. Helena MusauConsultant Clinical/Radiation Oncologist and Palliative Care Specialist \nSummary: \nTriple-Negative Breast Cancer: Contemporary Clinical Updates\nPresentation by Dr Joseph Abuodha\n \nDr Joseph Abuodha\, Consultant Medical Oncologist\, delivered a comprehensive clinical update on the biology\, diagnosis and management of triple-negative breast cancer (TNBC)\, highlighting its aggressive nature\, molecular heterogeneity and disproportionate burden in African populations. \nThe presentation outlined the distinctive pathological and molecular characteristics of TNBC\, emphasizing the absence of hormone receptor and HER2 expression\, high-grade histology and frequent genomic instability. Local and global epidemiological data were reviewed\, underscoring the higher prevalence and mortality associated with TNBC in African and African-descended populations. \nManagement strategies across the disease spectrum were discussed\, with chemotherapy reaffirmed as the backbone of treatment in non-metastatic disease. Dr Abuodha highlighted the growing role of neoadjuvant therapy\, particularly for stage II and III disease\, noting that achievement of pathologic complete response (pCR) remains a critical prognostic marker. Evidence supporting the incorporation of platinum agents and immune checkpoint inhibitors in selected patients was reviewed\, alongside adjuvant strategies for residual disease\, including capecitabine and PARP inhibitors in BRCA-mutated cancers. \nIn the metastatic setting\, the importance of repeat biopsy and molecular reassessment was emphasized to guide therapy. Emerging systemic options including immunotherapy\, PARP inhibitors and antibody–drug conjugates were discussed in the context of treatment sequencing and patient selection\, alongside the central role of supportive and palliative care. \nKey takeaway: Triple-negative breast cancer requires a biologically informed\, stage-adapted treatment approach\, with increasing emphasis on neoadjuvant strategies\, molecular testing and integration of novel systemic therapies to improve outcomes in high-risk populations.
URL:https://kesho-kenya.org/event/triple-negative-breast-cancer-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-30-at-9.56.23-AM-e1759236176125.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250925T190000
DTEND;TZID=Africa/Nairobi:20250925T203000
DTSTAMP:20260423T205651
CREATED:20250923T090118Z
LAST-MODIFIED:20250923T091234Z
UID:40433-1758826800-1758832200@kesho-kenya.org
SUMMARY:Prostate Cancer Awareness
DESCRIPTION:[vc_row][vc_column][vc_column_text] \n\nTheme: Advancing Prostate Cancer Awareness\nDate: 25th September 2025\nTime: 7 PM – 8:30 PM EAT\n\nModerator: Prof. Mungai Ngugi (Consultant Urologist & Transplant Surgeon\, Upper Hill Medical Center & Director\, East Africa Kidney Institute) \nSpeakers: \n\nH.E. Prof. Peter Anyang’ Nyong’o (Governor\, Kisumu County)\nDr. Amina K. Habib (Medical Oncologist\, Aga Khan University Hospital\, Nairobi)\nProf. Nicholas Othieno Abinya (Professor of Medicine\, Medical Oncologist\, The Nairobi Hospital)\n\nOrganizers/Sponsors: \n\nKenya Society of Haematology & Oncology (KESHO)\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_QvPa4Ky7RoGRhd1f_yr2lw”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/prostate-cancer-awareness/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-23-at-11.03.20-AM-e1758618147859.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250918T190000
DTEND;TZID=Africa/Nairobi:20250918T203000
DTSTAMP:20260423T205651
CREATED:20250915T115752Z
LAST-MODIFIED:20250916T123756Z
UID:40417-1758222000-1758227400@kesho-kenya.org
SUMMARY:Management of CML Blast Crisis
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nMANAGEMENT OF CML Blast Crisis \n📅 Date: 18th September 2025⏰ Time: 7 PM – 8:30 PM EAT \nMODERATORDr. Angela McligeyoPhysician and Medical Oncologist \nSPEAKERProfessor Gianantonio RostiIRCCS IRST “Dino Amadori”\, Meldola (Italy)Managing CML in Blast Crisis When Intensive Treatment Options are Available \nSPEAKERProfessor Malkit RiyatAssociate Professor of Haematology & Consultant Haematologist\, Aga Khan University Hospital\, NairobiManaging CML in Blast Crisis When Intensive Treatment Options are Limited \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=” Click to Register” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_dqr0xaQTQ4azL00zAgi9Aw”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cml-blast-crisis/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-16-at-11.46.45-AM-e1758026251987.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250911T190000
DTEND;TZID=Africa/Nairobi:20250911T203000
DTSTAMP:20260423T205651
CREATED:20250909T145133Z
LAST-MODIFIED:20250909T150805Z
UID:40404-1757617200-1757622600@kesho-kenya.org
SUMMARY:Palliative Support and Pain Management
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Moderator: \n\nDr. Zipporah Ali – Palliative Care Physician and Public Health Specialist\n\nSpeakers: \n\nDr. Lee Ngugi – Pain Management Specialist\, Anaesthesiologist & Lecturer\, Kenyatta University\, School of Medicine\, NairobiTopic: Interventional Pain Management Procedures in Cancer-Related Pain\nDr. Esther Munyoro – Neuro-anaesthetist & Palliative Care Specialist\, Former Head of Pain and Palliative Care Unit\, Kenyatta National Hospital\, NairobiTopic: Palliative care: Making it real\n\n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_btn title=”REGISTER” color=”danger” css=””][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/support-and-pain-management/
CATEGORIES:Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-09-at-1.11.19-PM-e1757429658184.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250904T190000
DTEND;TZID=Africa/Nairobi:20250904T203000
DTSTAMP:20260423T205651
CREATED:20250902T070734Z
LAST-MODIFIED:20250902T074433Z
UID:40392-1757012400-1757017800@kesho-kenya.org
SUMMARY:Paediatric Bone Marrow Transplantation
DESCRIPTION:[vc_row][vc_column][vc_column_text] \nDate & Time:📅 4th September 2025🕖 7:00 PM – 8:30 PM (EAT) \nModerator:Dr. Robert KimutaiConsultant Paediatrician & Haematologist-Oncologist\,MP Shah Hospital\, Nairobi \nSpeaker:Dr. Brian NderuConsultant Paediatrician & Haematologist-Oncologist\,Gertrude’s Children’s Hospital\, NairobiTopic: Paediatric Bone Marrow Transplant: Immense Possibilities \n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_4YrYt-keT5yLYGrVG-811Q”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/bone-marrow-transplantation/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/09/WhatsApp-Image-2025-09-02-at-9.30.03-AM-e1756796966321.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250828T190000
DTEND;TZID=Africa/Nairobi:20250828T193000
DTSTAMP:20260423T205651
CREATED:20250828T155020Z
LAST-MODIFIED:20250828T160124Z
UID:40384-1756407600-1756409400@kesho-kenya.org
SUMMARY:Cancer Care
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nModerator: \n\nDr. Anne Mwirigi – Consultant Haematologist & Assistant Professor\, Aga Khan University Hospital\, Nairobi\n\nSpeakers: \n\nDr. Arjun Ghosh – Consultant Cardiologist\, Barts Heart Centre (BHC)\, St. Bartholomew’s Hospital\, London & University College London Hospital\nDr. Manel Haj Mansour – Consultant Medical Oncologist & Section Head of Medical Oncology\, Aga Khan University Hospital\, Nairobi\nDr. Charles Kariuki – Interventional Cardiologist\, Ubora Heart\, The Nairobi Hospital\nDr. Gladwell Kiarie – Medical Oncologist\, The Nairobi Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_8tHcTBq9RQyHW5ptZ_-OdA”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-care/
CATEGORIES:CME 2023,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-28-at-7.05.53-AM-e1756396849381.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250807T190000
DTEND;TZID=Africa/Nairobi:20250807T203000
DTSTAMP:20260423T205651
CREATED:20250805T170900Z
LAST-MODIFIED:20250805T174804Z
UID:40344-1754593200-1754598600@kesho-kenya.org
SUMMARY:Cervical Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””] \nSpeakers:\n\nDr. Dulcie Wanda\n\n\nClinical & Radiation Oncologist\nHead of Department\, Nakuru Regional Cancer Treatment Centre\n\nTopic: Radiotherapy in Management of Advanced Cancer of the Cervix. \n2. Dr. Edward Sang \n\nGynaecologist and Oncologist\, MP Shah Doctors Plaza\, Nairobi\n\nTopic: Surgical Techniques in Cervical Cancer \nModerator:\nDr. Afrin Fatima Shaffi \n\nGynecologic Oncologist\, Nairobi West Hospital\n\n[/vc_column_text][vc_btn title=”REGISTER” color=”danger” css=”” link=”url:https%3A%2F%2Fus02web.zoom.us%2Fwebinar%2Fregister%2FWN_KINXix7MSqys9Q4p_rWZhQ”][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cervical-cancer-3/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/08/WhatsApp-Image-2025-08-05-at-4.13.55-PM-1-e1754414483969.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250731T190000
DTEND;TZID=Africa/Nairobi:20250731T203000
DTSTAMP:20260423T205651
CREATED:20250414T202143Z
LAST-MODIFIED:20250806T123353Z
UID:24416-1753988400-1753993800@kesho-kenya.org
SUMMARY:Bone Marrow Transplant
DESCRIPTION:Date: 31 July 2025 | 7:00 – 8:30PM EAT \nModerator: Dr Matilda Ongondi \nDr. Rohini Radia – Bone Marrow Transplantation  \nBone marrow transplantation (BMT) is a potentially curative treatment for various blood cancers and benign hematologic conditions like sickle cell disease and aplastic anemia. It involves high-risk procedures requiring meticulous planning and long-term follow-up. \nThere are two main types: \nAutologous (using the patient’s own cells) and Allogeneic (using donor cells). Allogeneic BMT carries a higher treatment-related mortality (10–25%) and risk of complications such as graft-versus-host disease (GVHD)\, infections\, and infertility\, but it is the only curative option for several conditions. Autologous BMT is safer (TRM <5%) and commonly used in myeloma and lymphomas. \nPatient and donor selection\, conditioning protocols\, and GVHD prophylaxis are tailored individually. Long-term follow-up is essential\, especially due to chronic GVHD and relapse risks. In sickle cell disease\, allogeneic HSCT offers a potential cure but requires careful risk-benefit consideration. \nSuccess in BMT depends on early identification\, thorough preparation\, and sustained multidisciplinary care beyond the immediate post-transplant period.
URL:https://kesho-kenya.org/event/bone-marrow-transplant/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250801-WA0000-e1754042861975.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250724T190000
DTEND;TZID=Africa/Nairobi:20250724T203000
DTSTAMP:20260423T205651
CREATED:20250414T201502Z
LAST-MODIFIED:20250806T120327Z
UID:24407-1753383600-1753389000@kesho-kenya.org
SUMMARY:Sarcoma Care
DESCRIPTION:Bridging Gaps in Soft Tissue Sarcoma Care \nDate: 24 July 2025 | 7:00 – 8:30pm EAT \nModerator: Dr Rose Munge \nDr Mohammed Ezzi – Beyond the Visible: Unmasking Soft Tissue Sarcoma in the Heart of Africa\nSoft tissue sarcomas are rare malignant tumors of mesenchymal origin\, accounting for under 1% of adult cancers. A review at Kenyatta National Hospital showed large tumor sizes (avg. 13 cm)\, high recurrence (78%)\, and better outcomes with radical excisions. \nChemotherapy regimens in Ethiopia predominantly included Adriamycin-based combinations. However\, access to radiotherapy remains limited\, impacting outcomes. Timely radiotherapy\, as seen in Tanzania\, improves survival. \nKey gaps include limited resources\, lack of local treatment guidelines\, and minimal access to specialists. Future efforts should focus on building regional sarcoma centers\, local research\, and developing Africa-specific management guidelines.
URL:https://kesho-kenya.org/event/sarcoma/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Sarcoma-Care-e1754481435270.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250717T190000
DTEND;TZID=Africa/Nairobi:20250717T203000
DTSTAMP:20260423T205651
CREATED:20250414T201147Z
LAST-MODIFIED:20250806T114844Z
UID:24403-1752778800-1752784200@kesho-kenya.org
SUMMARY:Endometrial Cancer
DESCRIPTION:Moderator: Dr Anisa Mburu\n1. Dr. Caroline Tonio – Advanced Endometrial Cancer\nDr. Tonio’s presentation highlighted significant advancements in the treatment of advanced and recurrent endometrial cancer. With rising incidence and poor outcomes in late-stage disease\, treatment has evolved from conventional chemotherapy to biomarker-driven strategies. \nMolecular subtyping\, as identified by the TCGA\, has enabled the use of immune checkpoint inhibitors (ICIs) and targeted therapies. Notably\, ICIs like dostarlimab and pembrolizumab show strong efficacy in dMMR/MSI-H tumors. Emerging combinations of ICIs with chemotherapy or TKIs are improving survival outcomes. The integration of molecular profiling is now essential in selecting optimal therapies. Future care will increasingly rely on predictive biomarkers to guide personalized treatment. \n2. Dr. Khadija Warfa – Endometrial Cancer Pathology and Surgical Staging\nDr. Warfa provided an overview of the pathology\, risk factors\, and staging of endometrial cancer. Most cases occur in postmenopausal women\, with abnormal bleeding as a common symptom. Risk factors include estrogen exposure\, obesity\, and genetic syndromes. \nDiagnosis relies on biopsy and imaging. Pathologically\, cancers are divided into Type I and II\, with molecular subtypes (e.g.\, POLE\, dMMR\, p53-abn) offering greater prognostic value. \nStandard surgical management involves hysterectomy with lymph node assessment. Sentinel lymph node biopsy is preferred in many cases due to lower complication rates. Minimally invasive approaches offer comparable survival outcomes with reduced morbidity.
URL:https://kesho-kenya.org/event/endometrial-cancer-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/04/unnamed-e1752574943250.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250710T190000
DTEND;TZID=Africa/Nairobi:20250710T203000
DTSTAMP:20260423T205651
CREATED:20250414T201718Z
LAST-MODIFIED:20250806T125314Z
UID:24409-1752174000-1752179400@kesho-kenya.org
SUMMARY:Prostate Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Date: 10 July 2025 | Time: 7:00 – 8:30PM EAT \nModerator: Dr Ahmed Komen \nDr Muigai Mararo – Management Algorithm for Metastatic Prostate Cancer\nDr Mararo presented a concise framework detailing oligometastatic local therapies (stereotactic radiotherapy or nodal resection)\, first‑line androgen‑deprivation therapy (continuous orchiectomy or LHRH analogue) combined with AR pathway inhibitors or docetaxel (with or without triplet combinations)\, radiotherapy for low‑volume disease\, and the sequencing of novel agents (second‑generation antiandrogens\, PARP inhibitors\, radioligand therapy) in castration‑resistant settings\, alongside essential supportive measures (bone protection\, multidisciplinary review). \nDr. Syokau Ilovi – Role of Germline Genetic Testing in Prostate Cancer\nAbout 10% of prostate cancers harbor pathogenic germline variants (notably BRCA1/2 and other HRR genes)\, prompting universal testing in metastatic disease and selective panels in high‑risk localized cases; implementation includes multigene panels\, variant classification (pathogenic\, VUS)\, genetic counseling\, cascade testing for relatives\, and periodic reclassification to inform personalized therapy and family risk management. \nDr. Mercy Gatua – Advances in Management of Metastatic Prostate Cancer: The Role of PARP Inhibitors\nPARP inhibitors exploit homologous recombination repair deficiencies (up to 30% of mCRPC\, especially BRCA2 mutations) by inducing lethal double‑strand DNA breaks; key trials (TOPARP\, PROfound\, TRITON3\, PROpel) demonstrate significant rPFS and OS benefits as monotherapy or combined with AR pathway inhibitors in germline/somatic HRR‑mutated cohorts\, supporting FDA/EMA approvals and integration into first‑line and later‑line mCRPC treatment algorithms. \n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/prostate-cancer-6/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-07-07-at-11.29.37-AM-e1751892629661.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250703T190000
DTEND;TZID=Africa/Nairobi:20250703T203000
DTSTAMP:20260423T205651
CREATED:20250414T201819Z
LAST-MODIFIED:20250806T125526Z
UID:24411-1751569200-1751574600@kesho-kenya.org
SUMMARY:Lymphoma Management in Africa
DESCRIPTION:Date: 3 July 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Beatrice Jepngetich \nDr. Anne Mwirigi – Relapsed/Refractory DLBCL \nDr. Anne Mwirigi presented a stage IVB germinal-center DLBCL case to illustrate why approximately 14% of Kenyan patients fail standard R-CHOP\, highlighting that true primary-refractory disease carries a median survival under nine months. She emphasized early risk stratification using IPI scoring\, interim PET imaging\, and molecular markers to identify high-risk individuals. For chemosensitive relapses\, salvage regimens such as R-GDP and R-ICE can bridge to autologous stem cell transplant; however\, CAR-T therapy and CD3×CD20 bispecific antibodies deliver the highest response rates. Practical recommendations included confirming residual disease with biopsy\, accelerating cellular therapy referral in primary-progressive cases\, and advocating for regional access programs to overcome cost barriers. \nDr. Jonathan Wawire – High-Grade B-Cell Lymphoma Entities \nDr. Jonathan Wawire decoded the WHO 5th-edition classification of high-grade B-cell lymphomas\, clarifying that a Ki-67 index ≥80% and dual MYC/BCL2 or BCL6 rearrangements define the most aggressive subtypes. He noted Kenya’s elevated prevalence of non-GCB and double-expresser lymphomas\, which correlate with poorer outcomes and necessitate intensified regimens. Key diagnostic insights included routine Ki-67 quantification\, Hans/Choi cell-of-origin algorithms\, and reflex FISH panels for precise double-hit detection. He stressed that accurate subclassification is essential for deciding when to intensify therapy beyond R-CHOP—such as DA-EPOCH-R—or to enrol patients in clinical trials\, ensuring truly personalized care for aggressive lymphoma in African settings.
URL:https://kesho-kenya.org/event/lymphoma-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-29-at-8.28.07-AM-scaled-e1751238405443.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250625T190000
DTEND;TZID=Africa/Nairobi:20250625T203000
DTSTAMP:20260423T205651
CREATED:20251223T210004Z
LAST-MODIFIED:20251223T210004Z
UID:40823-1750878000-1750883400@kesho-kenya.org
SUMMARY:Sickle Cell Disease
DESCRIPTION:
URL:https://kesho-kenya.org/event/sickle-cell-disease-3/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250619T190000
DTEND;TZID=Africa/Nairobi:20250619T203000
DTSTAMP:20260423T205651
CREATED:20250414T202032Z
LAST-MODIFIED:20250806T125949Z
UID:24414-1750359600-1750365000@kesho-kenya.org
SUMMARY:Sickle Cell Disease
DESCRIPTION:Date: 19 June 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Peter Oyiro \nProf. Jessie Githang’a – Sickle Cell Clinical Trials in Kenya \nProf. Jessie Githang’a emphasized the need for more SCD clinical trials in Africa\, where the disease burden is greatest. She outlined the underrepresentation of African populations in global trials and highlighted the benefits of local research\, including better understanding of drug efficacy\, safety\, and socio-genetic differences. She discussed ongoing and past trials in Kenya involving Hydroxyurea\, Crizanlizumab\, and gene therapies\, noting challenges like infrastructure gaps and limited expertise. Prof. Githang’a called for improved research capacity\, team collaboration\, and greater engagement with trial participants. \nDr. Doreen Mutua – Management of SCD in the 21st Century \nDr. Doreen Mutua reviewed modern SCD management\, highlighting the importance of early diagnosis\, health maintenance\, and Hydroxyurea therapy. She addressed common complications like stroke\, chronic pain\, and organ damage\, and emphasized early intervention to prevent progression. Transition of care for adolescents\, genetic counseling\, and curative options such as HSCT and gene editing were also discussed. Her presentation underscored the need for advocacy\, access to comprehensive care\, and integration of newborn screening into national systems.
URL:https://kesho-kenya.org/event/sickle-cell-disease-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-17-at-2.30.46-PM-e1750160210228.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250618T190000
DTEND;TZID=Africa/Nairobi:20250618T203000
DTSTAMP:20260423T205651
CREATED:20251223T205914Z
LAST-MODIFIED:20251223T205914Z
UID:40821-1750273200-1750278600@kesho-kenya.org
SUMMARY:Cancer and Nutrition
DESCRIPTION:
URL:https://kesho-kenya.org/event/cancer-and-nutrition/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250612T190000
DTEND;TZID=Africa/Nairobi:20250612T203000
DTSTAMP:20260423T205651
CREATED:20250414T201057Z
LAST-MODIFIED:20250806T113038Z
UID:24400-1749754800-1749760200@kesho-kenya.org
SUMMARY:Clinical Nutrition in Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Dr Catherine Nyongesa \nSpeakers & Topics: \n\nKennedy Okinda: Medical Nutrition Therapy Cases in Cancer Care – A Cross‑Sector Lens\nTraceyann Njeri Wacheke: Medical Nutrition Therapy in Survivorship & Secondary Cancer Prevention\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/clinical-nutrition-in-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-06-at-10.42.37-AM-scaled-e1749240060528.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250611T190000
DTEND;TZID=Africa/Nairobi:20250611T203000
DTSTAMP:20260423T205651
CREATED:20251223T205807Z
LAST-MODIFIED:20251223T205807Z
UID:40819-1749668400-1749673800@kesho-kenya.org
SUMMARY:Palliative Care: Integrative  Oncology
DESCRIPTION:
URL:https://kesho-kenya.org/event/palliative-care-integrative-oncology/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250605T190000
DTEND;TZID=Africa/Nairobi:20250605T203000
DTSTAMP:20260423T205651
CREATED:20250414T200927Z
LAST-MODIFIED:20250622T142308Z
UID:24398-1749150000-1749155400@kesho-kenya.org
SUMMARY:Cancer Survivor's Day
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof John Weru \nSpeakers & Topics: \n\nMuthoni Mate: Tokenism in Cancer Survivor Involvement – Beyond Being the Face on a Brochure\nDr Mary Nyangasi: Beyond Remission – Best Practices in Survivorship Care Planning & Patient Navigation\nDr Esther Muinga: Palliative Care as a Pillar of Survivorship\n\nMuthoni Mate highlighted the issue of tokenism where survivors are symbolically included without influence. She called for shifting from consultation to co-design and recognizing survivors as experts by experience. Obstacles include medical jargon\, lack of trauma-informed engagement\, minimal institutional support\, and preference for academic voices. True engagement must be collaborative\, compensated\, and empowering\, allowing survivors to shape policy and practice. She urged stakeholders to move beyond the ‘face on the brochure’ and include survivors meaningfully in healthcare decision-making. \nDr. Nyangasi emphasized the critical role of survivorship care planning and patient navigation in ensuring long-term quality of life for cancer survivors. She outlined survivorship as a continuum beginning at diagnosis\, extending beyond acute care into surveillance\, psychosocial support\, and lifestyle guidance. Evidence from over 60 systematic reviews shows that patient navigation improves care access\, adherence to follow-up\, and satisfaction. Barriers in Kenya include weak health systems\, low awareness\, lack of funding\, and absence of integrated care protocols. There is urgent need for structured survivorship models and investment in navigation programs with proven return on investment. \nDr. Muinga presented palliative care as integral to survivorship\, aiming to improve quality of life through pain control\, emotional support\, and end-of-life care. She emphasized the interconnectedness of palliation\, prevention\, and health promotion. Effective survivorship care requires collaboration across disciplines and includes surveillance\, psychosocial screening\, and health education. Survivorship plans should empower patients and caregivers\, incorporate national policies\, and address financial and cultural challenges. She concluded that palliative care is not about dying—it’s about living fully post-treatment.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/cancer-survivors-day/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-05-29-at-9.36.30-AM-e1748516449351.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250604T190000
DTEND;TZID=Africa/Nairobi:20250604T203000
DTSTAMP:20260423T205651
CREATED:20251223T205510Z
LAST-MODIFIED:20251223T205705Z
UID:40817-1749063600-1749069000@kesho-kenya.org
SUMMARY:Cancer Survivorship
DESCRIPTION:
URL:https://kesho-kenya.org/event/cancer-survivorship/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250528T190000
DTEND;TZID=Africa/Nairobi:20250528T203000
DTSTAMP:20260423T205651
CREATED:20251223T205348Z
LAST-MODIFIED:20251223T205348Z
UID:40815-1748458800-1748464200@kesho-kenya.org
SUMMARY:Brain Cancer / Brain Tumour
DESCRIPTION:
URL:https://kesho-kenya.org/event/brain-cancer-brain-tumour/
CATEGORIES:CME 2026,Continuing Medical Education (CME)
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250524T083000
DTEND;TZID=Africa/Nairobi:20250524T160000
DTSTAMP:20260423T205651
CREATED:20250414T200830Z
LAST-MODIFIED:20250622T142308Z
UID:24396-1748075400-1748102400@kesho-kenya.org
SUMMARY:EA Oncology Summit
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]\n\n\n    Download    PDF Loading...\n    \n        \n    \n    \n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/ea-oncology-summit-2/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/04/Screenshot-2025-05-20-130129-scaled-e1750167427791.png
END:VEVENT
END:VCALENDAR